Interleukin 17F level and interferon beta response in patients with multiple sclerosis

JAMA Neurology

Volumn 70, Issue 8, 2013, Pages 1017-1021

  Hartung, Hans Peter ^a   Steinman, Lawrence ^d   Goodin, Douglas S ^e   Comi, Giancarlo ^f   Cook, Stuart ^g   Filippi, Massimo ^f   O'Connor, Paul ⁱ   Jeffery, Douglas R ^j   Kappos, Ludwig ^k   Axtell, Robert ^d   Knappertz, Volker ^l   Bogumil, Timon ^h   Schwenke, Susanne ^b   Croze, Ed ^h   Sandbrink, Rupert ^a,b   Pohl, Christopher ^b,c  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b BAYER PHARMA AG   (Germany)

^c UNIVERSITY HOSPITAL BONN   (Germany)

^d STANFORD UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^g RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^h BAYER CORPORATION   (United States)

ⁱ ST MICHAEL'S HOSPITAL   (Canada)

^j Multiple Sclerosis Center   (United States)

^k UNIVERSITY HOSPITAL BASEL   (Switzerland)

^l MEDIMMUNE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON BETA SERINE; INTERLEUKIN 17F;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG RESPONSE; FEMALE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL;

EID: 84882360092     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2013.192     Document Type: Article

References (20)

1. Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity. 2004;21(4):467-476.
2. Yang XO, Chang SH, Park H, et al. Regulation of inflammatory responses by IL-17F. J Exp Med. 2008;205(5):1063-1075.
3. Korn T, Bettelli E, OukkaM, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol. 2009;27: 485-517.
4. Mitsdoerffer M, Kuchroo V. New pieces in the puzzle: how does interferon-beta really work in multiple sclerosis? Ann Neurol. 2009;65(5): 487-488.
5. Axtell RC, de Jong BA, Boniface K, et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med. 2010;16(4):406-412.
6. Bǎlaşa R, Huţanu A, Bajko Z, Feier C, Pascu I. Does the serum IL-17 titer influence the efficacy of interferon-β treatment in multiple sclerosis patients? Rev Rom Med Lab. 2011;19:381-389.
7. O'Connor P, Filippi M, Arnason B, et al BEYOND Study Group. 250 microg or 500 microg interferon beta-1b vs 20mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009;8(10):889-897.
8. Todd J, Freese B, Lu A, et al. Ultrasensitive flow-based immunoassays using single-molecule counting. Clin Chem. 2007;53(11):1990-1995.
9. Risch N, Zhang H. Extreme discordant sib pairs for mapping quantitative trait loci in humans. Science. 1995;268(5217):1584-1589.
10. Ebers GC, Kukay K, Bulman DE, et al. A full genome search in multiple sclerosis. Nat Genet. 1996;13(4):472-476.
11. Greenberg J, Furer V, Lu QA, et al. Advanced single molecule detection accelerating biomarker development utilizing cytokines through ultrasensitive immunoassays. http://www.singulex .com/documents/CytoInflamm2012-FINAL.pdf. Accessed March 23, 2012.
12. Bushnell SE, Zhao Z, Stebbins CC, et al. Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remittingMS. Neurology. 2012;79(6): 531-537.
13. Haak S, Croxford AL, Kreymborg K, et al. IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation inmice. J Clin Invest. 2009;119(1):61-69.
14. Killestein J, Hartung HP. Interferon β in multiple sclerosis: predicting response at an early stage. J Neurol Neurosurg Psychiatry. 2008;79(6):616-617.
15. Comabella M, Lunemann JD, Rio J, et al. A type I interferon signature in monocytes is associated with poor response to interferon-β in multiple sclerosis. Brain. 2009;132(Pt 12):3353-3365.
16. van Baarsen LGM, Vosslamber S, Tijssen M, et al. Pharmacogenomics of interferon-β therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS One. 2008;3(4):e1927.
17. Croze E, Yamaguchi KD, Knappertz V, Reder AT, Salamon H. Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis [published online June 19, 2012]. Pharmacogenomics J. doi:10.1038/tpj.2012.27.
18. Rio J, Nos C, TintoreM, et al. Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients. Ann Neurol. 2006;59(2):344-352.
19. Rio J, Castillo J, Rovira A, et al. Measures in the first year of therapy predict the response to interferon β inMS. Mult Scler. 2009;15(7):848-853.
20. Killestein J, Polman CH. Determinants of interferon β efficacy in patients with multiple sclerosis. Nat Rev Neurol. 2011;7(4):221-228.